Galapagos NV (NASDAQ:GLPG) is Finepoint Capital LP’s 10th Largest Position

Finepoint Capital LP raised its position in Galapagos NV (NASDAQ:GLPG) by 21.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 674,762 shares of the biotechnology company’s stock after acquiring an additional 117,000 shares during the quarter. Galapagos makes up 1.1% of Finepoint Capital LP’s investment portfolio, making the stock its 10th largest position. Finepoint Capital LP owned 1.02% of Galapagos worth $18,556,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. R Squared Ltd purchased a new position in Galapagos during the 4th quarter valued at about $26,000. GAMMA Investing LLC raised its holdings in shares of Galapagos by 77.4% during the fourth quarter. GAMMA Investing LLC now owns 2,233 shares of the biotechnology company’s stock valued at $61,000 after acquiring an additional 974 shares in the last quarter. QRG Capital Management Inc. lifted its stake in Galapagos by 21.7% in the fourth quarter. QRG Capital Management Inc. now owns 10,455 shares of the biotechnology company’s stock worth $288,000 after acquiring an additional 1,866 shares during the period. American Century Companies Inc. boosted its holdings in Galapagos by 5.9% in the fourth quarter. American Century Companies Inc. now owns 25,852 shares of the biotechnology company’s stock valued at $711,000 after acquiring an additional 1,431 shares in the last quarter. Finally, Crossmark Global Holdings Inc. increased its position in Galapagos by 31.5% during the 4th quarter. Crossmark Global Holdings Inc. now owns 49,163 shares of the biotechnology company’s stock valued at $1,352,000 after purchasing an additional 11,777 shares during the period. 32.46% of the stock is owned by institutional investors.

Galapagos Stock Performance

GLPG opened at $23.75 on Friday. The company’s 50-day simple moving average is $25.13 and its two-hundred day simple moving average is $26.73. Galapagos NV has a 52-week low of $22.36 and a 52-week high of $32.17.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the stock. Morgan Stanley lowered shares of Galapagos from an “equal weight” rating to an “underweight” rating and cut their target price for the company from $31.00 to $22.00 in a research note on Friday, February 14th. TD Cowen cut Galapagos from a “strong-buy” rating to a “strong sell” rating in a research report on Thursday, January 9th. Finally, Barclays reissued an “underweight” rating on shares of Galapagos in a research report on Thursday, January 23rd. Four investment analysts have rated the stock with a sell rating and four have given a hold rating to the stock. According to data from MarketBeat.com, Galapagos currently has an average rating of “Hold” and an average price target of $25.33.

Galapagos Profile

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.